Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer

Abstract

The aim of our study was to evaluate the efficacy and toxicity of a bi-weekly chemohormonal regimen consisting of epirubicin, etoposide, and low-dose dexamethasone (EED) in patients with hormone-refractory prostate cancer (HRPC). Conclusion: Chemohormonal EED regimen proved to be active and well-tolerated in patients with HRPC.

Keywords

• Bi-weekly
• epirubicin
• etoposide
• low-dose
• dexamethasone
• hormone-refractory
• prostate
• cancer